BACKGROUND
HIV drug resistance (HIV-DR) is rising in sub-Saharan Africa in both ART-naive and ART-experienced patients.
HIV care provides an opportunity to integrate comprehensive sexual and reproductive healthcare, including sexually transmitted infection (STI) management.
Xpert MTB/RIF rapidly detects resistance to rifampicin (RR); however, this test misses I491F-RR conferring mutation, common in southern Africa. In addition, Xpert MTB/RIF does not distinguish between viable and dead (MTB).
This paper shows the scale of global health research and the context in which we frame the subsequent papers in the Series.
Evaluating whether an intervention works when trialled in groups of individuals can pose complex challenges for clinical research.
In global health research, short-term, small-scale clinical trials with fixed, two-arm trial designs that generally do not allow for major changes throughout the trial are the most common study design.
BACKGROUND: In low-and-middle-income countries (LMIC), data related to antimicrobial resistance (AMR) are often inconsistently collected.
